Collins, Peter W.;
Palmer, Benedict P.;
Chalmers, Elizabeth A.;
Hart, Daniel P.;
Liesner, Ri;
Rangarajan, Savita;
Talks, Katherine;
Williams, Michael;
Hay, Charles R. M.
Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011
You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011
Contributor:
Collins, Peter W.;
Palmer, Benedict P.;
Chalmers, Elizabeth A.;
Hart, Daniel P.;
Liesner, Ri;
Rangarajan, Savita;
Talks, Katherine;
Williams, Michael;
Hay, Charles R. M.
Published:
American Society of Hematology, 2014
Published in:
Blood, 124 (2014) 23, Seite 3389-3397
Description:
<jats:title>Key Points</jats:title>
<jats:p>Kogenate Bayer/Helixate NexGen was associated with a higher inhibitor incidence than Advate in 407 consecutive UK severe hemophilia A previously untreated patients. Other risk factors for inhibitor development were factor VIII genotype, ethnicity, and intensive treatment episodes.</jats:p>